Company / Operating Cash Flow
NOVAVAX INC Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$244.6M
FY2025
5-year range
-$714.0M / $322.9M
FY2021-FY2025
Trend
-180.3%
vs FY2024
Sector context
#181 of 216
Health Care
What the data says
NOVAVAX INC's operating cash flow of -$245M is lower than 84% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$714M in FY2023 to $323M in FY2021.
Based on SEC 10-K filings.
-$245M in FY2025.
Improved from -$714M to -$245M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 216This company -$244.6M Sector average $659.0M
▼
-137.1% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 180.3% year-over-year.
- Ranks #181 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$244.6M | -180.3% |
| FY2024 | -$87.3M | +87.8% |
| FY2023 | -$714.0M | -1578.3% |
| FY2022 | -$42.5M | -113.2% |
| FY2021 | $322.9M | +859.1% |
| FY2020 | -$42.5M | +70.6% |
| FY2019 | -$144.5M | +44.2% |
| FY2018 | -$258.8M | -105.2% |
| FY2017 | -$126.1M | -88.2% |
| FY2016 | -$67.0M | -47.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026